Učitavanje...

CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS

OBJECTIVE: To assess the relationship between CD56(bright) natural killer (NK) cells and multiple sclerosis (MS) disease activity in patients with relapsing-remitting MS treated with daclizumab high-yield process (DAC HYP). METHODS: Data were from patients enrolled in a 52-week randomized, double-bl...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neurol Neuroimmunol Neuroinflamm
Glavni autori: Elkins, J., Sheridan, J., Amaravadi, L., Riester, K., Selmaj, K., Bielekova, B., Parr, E., Giovannoni, G.
Format: Artigo
Jezik:Inglês
Izdano: Lippincott Williams & Wilkins 2015
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4309527/
https://ncbi.nlm.nih.gov/pubmed/25635261
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000065
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!